Cargando…

Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors

Unfavorable ratios between the number and activation status of effector and suppressor immune cells infiltrating the tumor contribute to resistance of solid tumors to T-cell based therapies. Here, we studied the capacity of FDA and EMA approved recombinant cytokines to manipulate this balance in fav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tähtinen, Siri, Kaikkonen, Saija, Merisalo-Soikkeli, Maiju, Grönberg-Vähä-Koskela, Susanna, Kanerva, Anna, Parviainen, Suvi, Vähä-Koskela, Markus, Hemminki, Akseli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479879/ https://www.ncbi.nlm.nih.gov/pubmed/26107883 http://dx.doi.org/10.1371/journal.pone.0131242

Ejemplares similares

Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance
por: Tähtinen, Siri, et al.
Publicado: (2015)

Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy
por: Vähä-Koskela, Markus, et al.
Publicado: (2015)

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
por: Havunen, Riikka, et al.
Publicado: (2016)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
por: Havunen, Riikka, et al.
Publicado: (2015)

Incomplete but Infectious Vaccinia Virions Are Produced in the Absence of Oncolysis in Feline SCCF1 Cells
por: Parviainen, Suvi, et al.
Publicado: (2015)

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles
por: Autio, Karoliina, et al.
Publicado: (2014)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

Tumor Restrictions to Oncolytic Virus
por: Vähä-Koskela, Markus, et al.
Publicado: (2014)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
por: Quixabeira, Dafne C. A., et al.
Publicado: (2022)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
por: Basnet, Saru, et al.
Publicado: (2022)

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
por: Zafar, Sadia, et al.
Publicado: (2020)

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
por: Havunen, Riikka, et al.
Publicado: (2018)

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
por: Kudling, Tatiana V., et al.
Publicado: (2022)

MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver
por: Ylösmäki, Erkko, et al.
Publicado: (2013)

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine
por: Quixabeira, D. C. A., et al.
Publicado: (2023)

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer
por: Liikanen, Ilkka, et al.
Publicado: (2022)

Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles
por: Autio, Karoliina P. M., et al.
Publicado: (2015)

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity
por: Hirvinen, Mari, et al.
Publicado: (2016)

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
por: Pakola, Santeri, et al.
Publicado: (2023)

Using BERT to identify drug-target interactions from whole PubMed
por: Aldahdooh, Jehad, et al.
Publicado: (2022)

Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5
por: Ahonen, Marko T., et al.
Publicado: (2010)

Oncolytic viruses in cancer therapy
por: Vähä-Koskela, Markus J.V., et al.
Publicado: (2007)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
por: Quixabeira, Dafne C. A., et al.
Publicado: (2021)

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting
por: Clubb, James H. A., et al.
Publicado: (2023)

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2015)

Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Exploration of databases and methods supporting drug repurposing: a comprehensive survey
por: Tanoli, Ziaurrehman, et al.
Publicado: (2020)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients
por: Taipale, Kristian, et al.
Publicado: (2018)

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma
por: Leivonen, Suvi-Katri, et al.
Publicado: (2019)

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features
por: Wang, Yinyin, et al.
Publicado: (2022)

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment
por: Hemminki, Kari, et al.
Publicado: (2022)

S175: SINGLE-CELL ANALYSIS REVEALS SOMATIC TP53 MUTATIONS EMERGE IN EARLY PROGENITOR CELLS BUT BECOME ENRICHED IN THE ERYTHROID LINEAGE IN ERCC6L2 DISEASE
por: Langohr, Laura, et al.
Publicado: (2023)

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021)

Streptococcus salivarius Probiotics to Prevent Acute Otitis Media in Children: A Randomized Clinical Trial
por: Sarlin, Suvi, et al.
Publicado: (2023)

Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring
por: Mäkinen, Lotta, et al.
Publicado: (2022)

Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment
por: Viúdez-Pareja, Cristina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l3adnujljfnb5uoi6d82ugasua